Moderna Inc. (NASDAQ: MRNA) saw its stock price climb nearly 12% on Friday, as renewed interest in the company's early-stage hantavirus vaccine program followed a deadly Andes virus outbreak aboard the MV Hondius luxury cruise ship. The outbreak, which has resulted in six confirmed cases and three fatalities, has put a spotlight on Moderna's messenger RNA (mRNA) technology platform at a time when the company is striving to diversify its revenue beyond COVID-19 vaccines.
Health authorities, including the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC), have assessed the broader public risk as low. However, they have recommended a 42-day quarantine for all passengers disembarking from the vessel. As of May 8, the WHO reported eight total cases, with six laboratory-confirmed as Andes virus, a strain of hantavirus known to cause severe respiratory complications. The WHO classified the risk for ship passengers and crew as moderate, while maintaining a low global risk assessment.
Moderna's hantavirus vaccine research began in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and the Vaccine Innovation Center at Korea University College of Medicine, prior to the current outbreak. The company's mRNA technology works by instructing cells to produce specific proteins that trigger an immune response, a platform that has already proven successful with its COVID-19 vaccine.
The investment case for Moderna's hantavirus program remains speculative at this stage. The project is still in early development, and there is currently no approved vaccine or specific antiviral treatment for Andes virus, according to the U.S. Centers for Disease Control and Prevention (CDC). Analysts caution that the stock's surge may be temporary if health authorities successfully contain the outbreak. "This is not COVID," Acting CDC Director Jay Bhattacharya told CNN, as reported by Reuters, emphasizing the difference in scale and risk compared to the pandemic.
Moderna's recent financial performance has provided some positive momentum. The company reported first-quarter revenue of $389 million, more than triple the figure from the same period last year, with nearly 80% of sales coming from outside the United States. Chief Financial Officer Jamey Mock indicated to Reuters that the U.S. COVID-19 vaccine market is expected to stabilize by 2026.
Beyond infectious diseases, Moderna is making strides in other areas. In a late-stage study involving over 40,000 adults aged 50 and older, the company's mRNA-based seasonal flu vaccine demonstrated a 26.6% higher efficacy compared to GSK's standard-dose flu vaccine. Additionally, Moderna is collaborating with Merck & Co., Inc. (NYSE: MRK) on a personalized cancer vaccine, which analysts see as a key part of the company's long-term growth strategy beyond COVID-19.
Bernstein analyst Courtney Breen noted that while near-term financials appear stable, investor focus will likely shift toward Moderna's oncology pipeline. "Near-term, things appear to have stabilized," Breen said, adding that attention will turn to the ex-COVID opportunity in oncology.
The hantavirus-related stock move serves as a reminder of Moderna's platform potential rather than a near-term revenue driver. Public health officials continue to manage the containment of the Andes virus outbreak, while investors weigh the company's post-COVID narrative against tangible product development. The question remains how much of Moderna's future growth will come from actual products versus promise.
